CoChat

Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer

Open access

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.

Abstract

Incomplete understanding of the metastatic process hinders personalized therapy. Here we report the most comprehensive whole-genome study of colorectal metastases vs. matched primary tumors. 65% of somatic mutations originate from a common progenitor, with 15% being tumor- and 19% metastasis-specific, implicating a higher mutation rate in metastases. Tumor- and metastasis-specific mutations harbor elevated levels of BRCAness. We confirm multistage progression with new components ARHGEF7/ARHGEF33. Recurrently mutated non-coding elements include ncRNAs RP11-594N15.3, AC010091, SNHG14, 3’ UTRs of FOXP2, DACH2, TRPM3, XKR4, ANO5, CBL, CBLB, the latter four potentially dual protagonists in metastasis and efferocytosis-/PD-L1 mediated immunosuppression. Actionable metastasis-specific lesions include FAT1, FGF1, BRCA2, KDR, and AKT2-, AKT3-, and PDGFRA-3’ UTRs. Metastasis specific mutations are enriched in PI3K-Akt signaling, cell adhesion, ECM and hepatic stellate activation genes, suggesting genetic programs for site-specific colonization. Our results put forward hypotheses on tumor and metastasis evolution, and evidence for metastasis-specific events relevant for personalized therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-07041-z

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Recurrent somatic small mutations on protein coding genes. Oncoprint representation of recurrently mutated genes with a cutoff of 4 samples (17%). The top annotation shows the tumor cell content (TCC) and estimated tumor ploidy. The color of the box indicates the type of mutation. Recurrently mutated genes are marked with D, T, M if they were also recurrently mutated (>2.5%) in the Giannakis et al./DFCI 2016 (D), TCGA provision (T) and Yaeger et al./MSK-CC 2018 cohorts (M) via cBioPortal
Fig. 1 Recurrent somatic small mutations on protein coding genes. Oncoprint representation of recurrently mutated genes with a cutoff of 4 samples (17%). The top annotation shows the tumor cell content (TCC) and estimated tumor ploidy. The color of the box indicates the type of mutation. Recurrently mutated genes are marked with D, T, M if they were also recurrently mutated (>2.5%) in the Giannakis et al./DFCI 2016 (D), TCGA provision (T) and Yaeger et al./MSK-CC 2018 cohorts (M) via cBioPortalCC BY · PubMed Central
Fig. 2 Recurrent somatic copy number aberrations and structural variations. Relative prevalence of somatic copy number aberrations (predicted by ACEseq) in high tumor cell content (TCC) primary tumors a and metastasis b samples, showing presence of at least one copy number gain (orange bars), copy number loss (blue bars), and LOH (red line) as a proportion of analyzed samples. Circular plots of recurrent (minimum of 3) somatic structural variations (SVs) in high TCC tumors c and metastasis d samples. The panels (from outside going inwards) represent small somatic variant recurrence per gene, genomic cytobands, copy number changes (predicted by SOPHIA), and recurrent SVs within TAD regions. As an example of SV heterogeneity, we show the SV landscape for CRC-005 tumor e and metastasis f. Arcs represent translocation and inversion events
Fig. 2 Recurrent somatic copy number aberrations and structural variations. Relative prevalence of somatic copy number aberrations (predicted by ACEseq) in high tumor cell content (TCC) primary tumors a and metastasis b samples, showing presence of at least one copy number gain (orange bars), copy number loss (blue bars), and LOH (red line) as a proportion of analyzed samples. Circular plots of recurrent (minimum of 3) somatic structural variations (SVs) in high TCC tumors c and metastasis d samples. The panels (from outside going inwards) represent small somatic variant recurrence per gene, genomic cytobands, copy number changes (predicted by SOPHIA), and recurrent SVs within TAD regions. As an example of SV heterogeneity, we show the SV landscape for CRC-005 tumor e and metastasis f. Arcs represent translocation and inversion eventsCC BY · PubMed Central
Fig. 3 Chromothripsis and negative selection of highly rearranged chromosomes. Chromosome copy number predictions of six samples a–f, showing predicted copy number of tumor (top) and metastasis (bottom) samples. Regions of chromothripsis-like rearrangements b, c, f and highly rearranged events not present in the metastasis a, d, e, f are highlighted in dashed red boxes
Fig. 3 Chromothripsis and negative selection of highly rearranged chromosomes. Chromosome copy number predictions of six samples a–f, showing predicted copy number of tumor (top) and metastasis (bottom) samples. Regions of chromothripsis-like rearrangements b, c, f and highly rearranged events not present in the metastasis a, d, e, f are highlighted in dashed red boxesCC BY · PubMed Central
Fig. 4 Pathway model of colorectal cancer molecular drivers. Cartoon model (top) and oncoprints (bottom) of somatically mutated genes within colorectal progression pathways. Models and oncoprints of recurrently mutated genes within β-catenin/Wnt a, growth factor & RAS b, and apoptosis signaling c pathways. Genes were identified based on mutual exclusivity analysis and literature. Genes identified to be mutated in this study are shown in green ovals
Fig. 4 Pathway model of colorectal cancer molecular drivers. Cartoon model (top) and oncoprints (bottom) of somatically mutated genes within colorectal progression pathways. Models and oncoprints of recurrently mutated genes within β-catenin/Wnt a, growth factor & RAS b, and apoptosis signaling c pathways. Genes were identified based on mutual exclusivity analysis and literature. Genes identified to be mutated in this study are shown in green ovalsCC BY · PubMed Central
Fig. 5 Genomic landscape of tumor and metastasis mutations in patient CRC-010. Model of progression of tumor and metastasis from normal epithelial cells a, mutational signatures for tumor (dark blue), shared (red), and metastasis (dark red)-specific mutations b, structural variations in tumor c and metastasis d and copy number profiles in tumor e and metastasis f. ATM is located in the small deleted segment of chromosome 11 in the tumor sample d
Fig. 5 Genomic landscape of tumor and metastasis mutations in patient CRC-010. Model of progression of tumor and metastasis from normal epithelial cells a, mutational signatures for tumor (dark blue), shared (red), and metastasis (dark red)-specific mutations b, structural variations in tumor c and metastasis d and copy number profiles in tumor e and metastasis f. ATM is located in the small deleted segment of chromosome 11 in the tumor sample dCC BY · PubMed Central
Fig. 6 Mutational signatures in colorectal cancer progression. Bar plot representation of absolute a, and normalized b COSMIC cancer mutational signatures within the strata of tumor-specific (dark blue), metastasis-specific (dark red) and shared (purple) somatic SNVs per patient with high tumor cell content (TCC). Unsupervised clustering of normalized exposures, with top annotation showing ploidy, estimated TCC and mutational status for TP53, KRAS, ARHGEF33, TCF7L2, and FBXW7 c. Box and whisker plot of distributions of normalized exposures between mutations that are tumor-specific (dark blue), metastasis-specific (dark red), and shared (purple) per patient d. Boxes denote the interquartile range, the middle line denotes the median, and the vertical lines outside the box denote the minimal and maximum range excluding outliers (which are 1.5 times the interquartile range)
Fig. 6 Mutational signatures in colorectal cancer progression. Bar plot representation of absolute a, and normalized b COSMIC cancer mutational signatures within the strata of tumor-specific (dark blue), metastasis-specific (dark red) and shared (purple) somatic SNVs per patient with high tumor cell content (TCC). Unsupervised clustering of normalized exposures, with top annotation showing ploidy, estimated TCC and mutational status for TP53, KRAS, ARHGEF33, TCF7L2, and FBXW7 c. Box and whisker plot of distributions of normalized exposures between mutations that are tumor-specific (dark blue), metastasis-specific (dark red), and shared (purple) per patient d. Boxes denote the interquartile range, the middle line denotes the median, and the vertical lines outside the box denote the minimal and maximum range excluding outliers (which are 1.5 times the interquartile range)CC BY · PubMed Central
Fig. 7 Model of colorectal cancer and metastasis progression and therapeutic implications. A summary cartoon of how recurrent somatic mutations identified within this study fit into established colorectal progression models a. The top cartoons represent the transition from normal epithelial cells to metastasis (left to right). Beneath the cartoons are tables of genes and genetic lesions that were mutated in our cohort, sorted in tables related to possible pathway function. Change of relative exposure to mutational signatures are shown as horizontal bars where the strength of exposure corresponds to the strength of color in the bar, relative to tumor evolution (left to right) b. Cartoon representation of lesion (stars) accumulation giving rise to tumor heterogeneity c. Balloons are colored according to pathways, as the table headers in a, showing mutations in Wnt (green), RAS (orange), TGF-β (blue) signaling, and mutations acquired in carcinogenesis (brown), and metastasis (dark brown) formation. We show events which might not give rise to further progression. Mutations with implications on therapy decision are shown in light blue boxes with rounded corners, and linked to boxes with therapy consideration via a thick black line a, b. Gray vertical dashed lines separate out lesions corresponding to truncal origin, tumor, and metastasis states
Fig. 7 Model of colorectal cancer and metastasis progression and therapeutic implications. A summary cartoon of how recurrent somatic mutations identified within this study fit into established colorectal progression models a. The top cartoons represent the transition from normal epithelial cells to metastasis (left to right). Beneath the cartoons are tables of genes and genetic lesions that were mutated in our cohort, sorted in tables related to possible pathway function. Change of relative exposure to mutational signatures are shown as horizontal bars where the strength of exposure corresponds to the strength of color in the bar, relative to tumor evolution (left to right) b. Cartoon representation of lesion (stars) accumulation giving rise to tumor heterogeneity c. Balloons are colored according to pathways, as the table headers in a, showing mutations in Wnt (green), RAS (orange), TGF-β (blue) signaling, and mutations acquired in carcinogenesis (brown), and metastasis (dark brown) formation. We show events which might not give rise to further progression. Mutations with implications on therapy decision are shown in light blue boxes with rounded corners, and linked to boxes with therapy consideration via a thick black line a, b. Gray vertical dashed lines separate out lesions corresponding to truncal origin, tumor, and metastasis statesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 140

Metadata

Authors
Ishaque, N., Abba, M. L., Hauser, C., Patil, N., Paramasivam, N., Huebschmann, D., Leupold, J. H., Balasubramanian, G. P., Kleinheinz, K., Toprak, U. H., Hutter, B., Benner, A., Shavinskaya, A., Zhou, C., Gu, Z., Kerssemakers, J., Marx, A., Moniuszko, M., Kozlowski, M., Reszec, J., Niklinski, J., Eils, J., Schlesner, M., Eils, R., Brors, B., & Allgayer, H.
Affiliations
  • German Cancer Research Center (DE)
  • Heidelberg University (DE)
  • University Medical Centre Mannheim (DE)
  • Medical University of Białystok (PL)
Corresponding author
Allgayer, Heike
Venue
Nature Communications
Published
2018-11-14
Volume
9
Issue
1
Pages
4782-4782
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2899802902
Cited by
132
References
71
Citations by year
2026: 4 · 2025: 9 · 2024: 16 · 2023: 25 · 2022: 24 · 2021: 28 · 2020: 16 · 2019: 10
FWCI
4.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • OPUS (Augsburg University) (submittedVersion, cc-by)
Funders
  • Deutsches Krebsforschungszentrum
  • Deutsche Forschungsgemeinschaft (AL 465/9-1)
  • Universität Heidelberg
  • Alfried Krupp von Bohlen und Halbach-Stiftung (70112168)
  • Deutsche Krebshilfe (70112168)
  • Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
colorectal cancer, metastasis, somatic mutations, tumor-specific mutations, common progenitor, BRCAness, SNHG14, 3' UTR mutations, efferocytosis, PD-L1, immunosuppression, PI3K/Akt signaling, cell adhesion, extracellular matrix, hepatic stellate cells, targeted therapy
MeSH terms
Whole Genome Sequencing, Anoctamins, Adenocarcinoma, Aged, Cell Adhesion, DNA-Binding Proteins, Extracellular Matrix, Female, Humans, Liver Neoplasms, Male, Membrane Proteins, Middle Aged, Neoplasm Metastasis, Nuclear Proteins, Transcription Factors, Colorectal Neoplasms, Signal Transduction, 3' Untranslated Regions, Receptor, Platelet-Derived Growth Factor alpha, RNA, Untranslated, BRCA2 Protein, Membrane Transport Proteins, Vascular Endothelial Growth Factor Receptor-2, Adaptor Proteins, Signal Transducing, TRPM Cation Channels, Proto-Oncogene Proteins c-cbl, Apoptosis Regulatory Proteins, Proto-Oncogene Proteins c-akt, Forkhead Transcription Factors, Hepatic Stellate Cells, Precision Medicine, Rho Guanine Nucleotide Exchange Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. https://app.cochat.ai/papers/10.1038/s41467-018-07041-z
The paper
Ishaque, N., Abba, M. L., Hauser, C., Patil, N., Paramasivam, N., Huebschmann, D., Leupold, J. H., Balasubramanian, G. P., Kleinheinz, K., Toprak, U. H., Hutter, B., Benner, A., Shavinskaya, A., Zhou, C., Gu, Z., Kerssemakers, J., Marx, A., Moniuszko, M., Kozlowski, M., . . . Allgayer, H. (2018). Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nature Communications. https://doi.org/10.1038/s41467-018-07041-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.